New 'Smart Bomb' drug trial offers hope for women with recurrent ovarian cancer
NCT ID NCT06843447
Summary
This study is testing a new targeted cancer drug called raludotatug deruxtecan in women whose ovarian cancer has returned after previous chemotherapy. The drug works like a 'smart bomb' that attaches to cancer cells and delivers treatment directly to them. Researchers want to find the safest dose and see if the drug helps shrink tumors, either alone or when combined with other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts Health NHS Trust ( Site 0401)
RECRUITINGLondon, London, City of, E1 1RD, United Kingdom
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 0301)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0304)
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0010)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center ( Site 0003)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 0202)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Royal Marsden Hospital ( Site 0402)
RECRUITINGFulham, England, SW3 6JJ, United Kingdom
Contact Phone: •••-•••-••••
-
START Mountain Region ( Site 0008)
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-••••
-
Shaare Zedek Medical Center ( Site 0201)
RECRUITINGJerusalem, 9103102, Israel
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0200)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
The Royal Marsden NHS Foundation Trust. ( Site 0403)
RECRUITINGSutton, England, SM2 5PT, United Kingdom
Contact Phone: •••-•••-••••
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-••••
-
University of Virginia Health System ( Site 0011)
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.